ClinicalTrials.gg
RecruitingNCT07358195Updated Oct 14, 2026

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

An Early Phase 1 interventional study of Venetoclax and Hematopoietic Cell Transplantation Conditioning Regimen in Kidney Failure Chronic, Stem Cell Transplant and Stem Cell Transplant Complications, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Massachusetts General Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Renal Insufficiency, Chronic by Massachusetts General Hospital — 4 open to participants now, 4 under way, none of them phase 3. Renal Insufficiency, Chronic · Massachusetts General Hospital.

Planned enrollment
9th of 12
3 · median 11
Started
2026
with 1 other
Phase 1
Only one
of the 13
Registered
13th of 13
by date

Among the 13 studies in Renal Insufficiency, Chronic by Massachusetts General Hospital, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1, and was the 13th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 13 studies in Renal Insufficiency, Chronic by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Renal Insufficiency, Chronic by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.

03

Conditions studied

  • Kidney Failure Chronic
  • Stem Cell Transplant
  • Stem Cell Transplant Complications
  • Tolerance
  • Hematologic Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient Inclusion Criteria:

  • Patient ages 18-70
  • Underlying hematological which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.
  • Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.
  • Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation
  • > 40% as measured by echocardiography or MUGA
  • , FVC, and DLCO > 50% of predicted as measured by standard PFTs
  • Total \< 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and , ALT, alkaline phosphatase all \< 5x institutions
  • ABO compatibility in the host vs. graft direction
  • Men and women of must agree to use a reliable method of during the treatment, and women should do so for a period of 1 year following the transplant.
  • Participants should be on dialysis or have a ≤ 35 ml/min
  • greater than 6 months
  • Recipient ability to understand and provide

Donor Inclusion Criteria:

  • HLA matched or haploidentical relative as defined by 3/6, 4/6, or 5/6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age
  • performance status 0 or 1
  • Excellent health per conventional pre-donor history (medical and psychosocial evaluation)

    • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \< 3 times the upper limit of normal and normal creatinine)
  • Compatible ABO blood group
  • Negative donor lymphocyte cross match
  • No positive testing for active viral infection (, , )
  • Donor ability to understand and provide informed consent
  • Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation

Exclusion Criteria:

  • Active serious infection
  • Participation in other drug use at the time of enrollment
  • Positivity for active infection with HIV, HCV, or HBV
  • ABO blood group incompatibility in the host-vs-graft direction
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Recipient

    Stem Cell and Kidney Transplant

    Drug: Venetoclax · Procedure: Hematopoietic Cell Transplantation Conditioning Regimen · Procedure: Kidney Transplant · Procedure: Hematopoietic Cell Transplantation

Interventions

  • Venetoclax 400mg orally once daily on days -8 through -1 with daily monitoring for tumor lysis syndrome. Venetoclax tablets will be swallowed (not crushed). Venetoclax dosing will not be repeated in the event of vomiting.

  • ProcedureHematopoietic Cell Transplantation Conditioning Regimen

    Cytoxan Day -6 \& -5 Fludarabine Day -4, -3, -2 TBI Day -1

  • ProcedureKidney Transplant

    Living donor kidney transplant

  • ProcedureHematopoietic Cell Transplantation

    Donor bone marrow (target of 4 x 108 nucleated cells/kg of recipient ideal body weight) PBSC A goal dose of 5 x 106 CD34+ cells / kg of recipient actual body weight will be infused (minimum acceptable is 2 x 106 CD34+ cells / kg).

06

What researchers measure

Primary outcomes

  1. Incidence of full donor chimerism

    Time frame: 24 months

  2. Incidence of Grade IV Toxicity due to Venetoclax

    NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Days -8 to Days -1

  3. Incidence of Grade V Toxicity due to Venetoclax

    NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Days -8 to Days -1

Secondary outcomes

  1. Incidence of acute renal allograft rejection

    Time frame: 24 months

  2. Incidence of delayed renal allograft rejection

    Time frame: 24 months

  3. Incidence of acute GVHD

    Time frame: 24 months

  4. Incidence of Chronic GVHD

    Time frame: 24 months

  5. Patient Survival Rate

    Time frame: 24 months

  6. Allograft Survival Rate

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2030, 58 months after the start.

Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 58 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Jul 2026 → Feb 2026, primary completion Dec 2028 → Dec 2030 and completion Dec 2029 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 22, 2026
StartActual
Feb 4, 2026was Jul 2026
Primary completionEst.
Dec 2030was Dec 2028
CompletionEst.
Dec 2031was Dec 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
Massachusetts General Hospital is now Recruiting
Oct 14, 2026
Start date
Jul 2026→Feb 4, 2026 (actual)
Oct 14, 2026
Primary completion
Dec 2028→Dec 2030
Oct 14, 2026
Study completion
Dec 2029→Dec 2031
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    Massachusetts General Hospital is now Recruiting
    Start date Jul 2026→Feb 4, 2026 (now actual)
    Primary completion Dec 2028→Dec 2030
    Study completion Dec 2029→Dec 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07358195
Responsible party
Thomas Spitzer (Professor of Medicine, Harvard Medical School Director Emeritus, Bone Marrow Transplant Program, Massachusetts General Hospital) — Principal investigator
First posted
Jan 22, 2026
Start date
Feb 4, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Thomas Spitzer, MD
Contact
tspitzer@mgh.harvard.edu
617-724-1124

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion